pneumococcal polysaccharide serotype 19A

Pneumococcal polysaccharide serotype 19A is a purified capsular polysaccharide derived from *Streptococcus pneumoniae* serotype 19A. In the context of development by Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), it is typically formulated as a conjugate vaccine where the polysaccharide is chemically linked to a carrier protein (such as CRM197) to enhance immunogenicity, particularly in infants and the elderly. Serotype 19A became a major cause of invasive pneumococcal disease (IPD) following the introduction of earlier 7-valent vaccines that did not include it. The vaccine works by inducing B-cell and T-cell dependent immune responses, leading to the production of opsonophagocytic antibodies that protect against infection, pneumonia, and meningitis caused by this specific serotype.

Other names

pneumococcal serotype 19A polysaccharideStreptococcus pneumoniae serotype 19A capsular polysaccharide